Forskning ved Københavns Universitet - Københavns Universitet


Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma - A clinical, phase 1/2 trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • A. Berntsen
  • R. Trepiakas
  • L. Wenandy
  • P.F. Geertsen
  • P.T. Straten
  • M.H. Andersen
  • A.E. Pedersen
  • M.H. Claesson
  • T. Lorentzen
  • J.S. Johansen
  • I.M. Svane
Therapeutic dendritic cell (DC) vaccination against cancer is a strategy aimed at activating the immune system to recognize and destroy tumor cells. In this nonrandomized phase 1/2 trial, we investigated the safety, feasibility, induction of T-cell response, and clinical response after treatment with a DC- based vaccine in patients with metastatic renal cell carcinoma. Twenty-seven patients with progressive cytokine-refractory metastatic renal cell carcinoma were vaccinated with DCs loaded with either a cocktail of survivin and telomerase peptides or tumor lysate depending on their HLA-A2 haplotype, and low-dose IL-2 was administered concomitantly. Tumor response, immune response, and serum IL-6 and YKL-40 were measured during treatment. Vaccine generation was Successful in all patients and no serious adverse events were observed. None of the patients had an objective response but 13/27 patients obtained disease stabilization (SD) for more than 8 weeks. An antigen-specific immune response was demonstrated in 6/6 patients tested. Furthermore, significant alterations in serum YKL-40 and IL-6 were found during treatment. In conclusion, DC vaccination in our setting is feasible and without severe toxicity. Almost half of the patients obtained SID, and in more than 1/3 of the patients, SD persisted for more than 6 months. However, the evaluation of SD is difficult to interpret in the absence of a randomized trial and, therefore, these results should be interpreted with caution. Antigen-specific immune responses were observed in a subset of the treated patients
Udgivelsesdato: 2008/10
TidsskriftJournal of Immunotherapy
Udgave nummer8
Sider (fra-til)771-780
Antal sider9
StatusUdgivet - 2008

Bibliografisk note

Times Cited: 0ArticleEnglishSvane, I. MHerlev Hosp, CCIT, Dept Oncol, Herlev Ringvej 75, DK-2730 Herlev, DenmarkCited References Count: 53352NDLIPPINCOTT WILLIAMS & WILKINS530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USAPHILADELPHIA

ID: 13834561